![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 11, 2019 11:41:15 AM
The problem with Oncosec’s current IRES-based plasmid construct and electroporation voltage parameters is that transfection is not optimal, nor is IL-12 expression. If you don’t see adequate IL-12 levels being expressed intratumorally, odds are pretty good that you also won’t observe elevated levels of interferon gamma (and subsequent expression of STAT 1 genes); you won’t observe high T-bet levels, but higher Eomes and more T cell exhaustion; greater Treg ratios; poor tumor antigen presentation; and fewer chemokines that draw T cells into the TME.
I think “Spark”, the new multigene product, will undoubtedly resolve these issues and effectively reduce or completely eliminate the need for anti-PD-1 agents.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM